Microbiota and Carcinogenesis of Small-intestine Neuroendocrine Tumors

NCT ID: NCT06624865

Last Updated: 2025-04-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

75 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-11-05

Study Completion Date

2029-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to investigate the impact of the microenvironment on tumorigenesis of small intestinal neuroendocrine tumors often located in the terminal ileum, without identified driver mutations.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Small-intestine Neuroendocrine Tumors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patient with indication for small-intestine neuroendocrine tumor surgery

The target population for this study is consecutive patients with small-intestine neuroendocrine tumor for whom surgery is indicated

Blood and stool sampling

Intervention Type OTHER

Blood and stool sampling

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood and stool sampling

Blood and stool sampling

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with one or more small-intestine neuroendocrine tumor with indication of surgery
* Patient with consent for the collection, storage and reuse of data associated with his/her disease
* Age ≥ 18 years at the time of inclusion
* Non-objection statement obtained for participation in the study

Exclusion Criteria

* Patients with poorly differentiated neuroendocrine carcinoma or NET (neuroendocrine tumors) of non-intestinal origin or mixed tumors (MiNEN)
* Pregnant, parturient or breast-feeding women
* Minors
* Persons deprived of liberty by judicial or administrative decision
* Adults under legal protection (guardianship, curatorship)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospices Civils de Lyon

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Edouard Herriot University Hospital

Lyon, France, France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Thomas WALTER, MD, PhD

Role: CONTACT

0472117398 ext. +33

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Thomas WALTER, MD, PhD

Role: primary

0472117398 ext. +33

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2023-A02667-38

Identifier Type: OTHER

Identifier Source: secondary_id

69HCL23_1290

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Microbiome and Rectal Cancer
NCT04223102 ACTIVE_NOT_RECRUITING NA
Immunotherapy Treating GI Cancer
NCT03614650 UNKNOWN PHASE1/PHASE2